Patient characteristics by multiple sclerosis (MS) pattern
| RMS N (%) | SPMS N (%) | PPMS N (%) | |
| 278 (78.3) | 47 (13.2) | 30 (8.5) | |
| Median disease duration in years (IQR) | 12.0 (6.5–18.4) | 18.7 (12.1–23.7) | 12.7 (7.7–17.2) |
| Mean number of doses (SD) | 3.9 (1.7) | 4.1 (1.6) | 3.9 (1.5) |
| Median time in months on OCR (IQR) | 24.8 (16.8–29.5) | 28.7 (23.4–30.4) | 26.0 (23.4–29.8) |
| ARR 24 months prior to OCR (SD) | 0.34 (±0.42) | 0.14 (±0.34) | 00 |
| Previous DMT, % (n) | |||
| Interferon | 9 (3.3) | 2 (4.3) | 0 |
| Glatiramer acetate | 18 (6.6) | 4 (8.5) | 1 (3.4) |
| Fingolimod | 45 (16.4) | 6 (12.8) | 2 (6.9) |
| Dimethyl fumarate | 47 (17.2) | 4 (8.5) | 2 (6.9) |
| Teriflunomide | 18 (6.6) | 2 (4.3) | 2 (6.9) |
| Natalizumab | 59 (21.5) | 5 (10.6) | 2 (6.9) |
| Other Med* | 19 (6.9) | 4 (8.5) | 5 (17.2) |
| Treatment naive | 59 (21.5) | 20 (42.6) | 17 (58.6) |
| Median baseline EDSS (IQR) | 3.0 (2–4) | 6.5 (6–7.5) | 6.5 (6.0–7.0) |
| Median EDSS (IQR) at 12 months (n) | 3.0 (2.0–5.5) (151) | 6.5 (6.5–7.5) (31) | 6.5 (5.6–7.5) (16) |
*Other Med includes mycophenolate, intravenous methylprednisolone, daclizumab, cyclophosphamide, azathioprine, and study drugs through clinical trials.
EDSS, Expanded Disability Status Scale; PPMS, primary progressive MS; RMS, relapsing MS; SPMS, secondary progressive MS.